TRPX - Therapix Biosciences Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.48
+0.22 (+4.18%)
As of 11:08AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.26
Open5.22
Bid5.36 x 3100
Ask5.38 x 1100
Day's Range5.16 - 5.82
52 Week Range3.00 - 7.69
Volume239,797
Avg. Volume198,017
Market Cap19.164M
Beta (3Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-1.56
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • ACCESSWIRE10 days ago

    Therapix Biosciences, Cannabis Based Drug Candidates Pipeline Review

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Therapix Biosciences Ltd. (TRPX) is a specialty clinical-stage pharmaceutical company creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. On October 1st, TRPX shares closed at $4.57 and have since then hit an intra-day high of $7.65 (+67%). Combining PEA with THC may stimulate cannabinoid receptors, inhibit metabolic degradation, and thus increase uptake of THC.

  • ACCESSWIRE2 months ago

    Clinical Stage Marijuana Focused Biotech Stocks Trend Higher In August

    CORAL GABLES, FL / ACCESSWIRE / August 30, 2018 / Typically the stock market slows down toward the end of summer but this year that has not been the case. The markets are hitting all time highs and one of the top sectors leading the charge: biotechnology. Big pharma is weighing in on clinical stage companies as smaller biotechnology companies are benefiting big after multi-million dollar strategic investments and a strong M&A climate.

  • Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
    PR Newswire2 months ago

    Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , Aug. 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, ...

  • PR Newswire3 months ago

    Therapix Biosciences Announces Positive Data From Recent Pre-clinical Studies for its Drug Candidate THX-160 for Treatment of Pain

    TEL AVIV, Israel, July 17, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical studies evaluating THX-160, a novel pharmaceutical CB2 Receptor agonist for the treatment of pain. This innovative CB2 receptor agonist, which was found to be superior out of two candidates the Company had tested, was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, and a member of the Therapix Scientific Advisory Board. To date, prescription opioids are considered to be the most effective treatment for moderate-to-severe pain, but their abuse has been identified by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) as a significant public health issue.

  • Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical
    PR Newswire3 months ago

    Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical

    The term sheet entered into is non-binding and subject to ongoing due diligence and the entry into of definitive agreements and the fulfillment of certain agreed conditions. Pursuant to the term sheet, the parties propose that Therapix will receive newly issued shares in CURE in exchange for the assets, and Therapix will as a result become a significant shareholder in CURE.

  • Therapix Biosciences Updates Regarding TASE Delisting
    PR Newswire4 months ago

    Therapix Biosciences Updates Regarding TASE Delisting

    In coordination with the TASE, the Shares will be delisted from the TASE on August 9, 2018 ("Delisting Date"), and until the Delisting Date, Therapix's Shares will continue to be traded on the TASE. The last trading day in which the Shares are to be traded on TASE will be August 7, 2018.

  • Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
    PR Newswire4 months ago

    Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

    TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces sponsorship of the 11th  European Society for the Study of Tourette Syndrome (ESSTS) conference, in Copenhagen Denmark, on June 13th until June 15th, as part of the Company's strategy to develop therapy for Tourette's patients and to support the Tourette's community.

  • Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug
    PR Newswire4 months ago

    Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug

    TEL AVIV, Israel, June 5, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company's cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest private hospital network in Israel.

  • Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
    PR Newswire5 months ago

    Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , May 31, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX)  a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, ...

  • PR Newswire5 months ago

    Therapix Biosciences Issues CEO's Letter to Shareholders

    TEL AVIV, Israel, May 15, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, issued today a letter to its shareholders, from the CEO and chairman of the company. "Therapix Biosciences has experienced an encouraging and optimistic start to 2018. All of these activities led to Q2 2018 being an important inflection point in our Company's development as we hope to see the fruits of these efforts in our product pipelines in each of our focus areas in drug development.

  • Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange
    PR Newswire5 months ago

    Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

    TEL AVIV, Israel, May 9, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (TASE: THXBY) ("Therapix" or "the Company"), a biopharmaceutical company focused on discovering, ...

  • InMed Announces Appointment of Joshua Blacher as Chief Business Officer
    CNW Group6 months ago

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

  • ACCESSWIRE6 months ago

    Blog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome Treatment

    Stock Monitor: Madrigal Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Therapix Biosciences Ltd (NASDAQ: TRPX ...

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Teva and Therapix

    NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Shares of Therapix were popping on Monday after positive trial results about the company's proprietary cannabinoid product platform THX-IIO fell upon the eyes ...

  • Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
    PR Newswire6 months ago

    Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

    "The successful completion of this study is a key milestone in our clinical development plan of our proprietary drug candidate THX-110 for the treatment of Tourette syndrome for which current available treatments are frequently inadequate or unsafe," said Adi Zuloff-Shani, Ph.D, Chief Technology Officer at Therapix. The study was a single-arm, open-label trial, in which each subject both received one daily treatment of the drug via oral administration and was followed-up for a period of 12 weeks.

  • Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
    PR Newswire7 months ago

    Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

    TEL AVIV, Israel, March 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for THX-110 in the treatment of Chronic Low Back Pain. Therapix expects to commence a Phase IIa clinical trial in the second quarter of 2018. "We believe that the clearance of this IND by the FDA is a significant milestone for Therapix and for its platform technology THX-110 and for patients suffering from chronic low back pain for whom existing medicines often do not provide adequate relief," stated Adi Zuloff-Shani, Ph.D, Therapix's Chief Technology Officer.

  • Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
    PR Newswire8 months ago

    Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

    TEL AVIV, Israel, Feb. 7, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it has held a pre-Investigational New Drug (pre-IND) communication with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome. "Following this informative communication with the FDA, we can confirm that the IND for THX-110 will not require any additional nonclinical data to support a phase IIb study in the the United States.

  • Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018
    PR Newswire9 months ago

    Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

    TEL AVIV, Israel, Jan. 9, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is expanding into precision medicine through a new fully-owned subsidiary in order to develop novel solutions for pain. This new subsidiary will complement the Company's cannabinoid-based drug development strategy.

  • Reuters10 months ago

    Therapix expects to have results of Tourette's drug trial by end of Q1

    Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues. It has completed enrolment of 16 patients for its Phase IIa study at Yale University, where it will assess the drug that combines a synthetic cannabinoid already approved by the U.S. Food and Drug Administration with a fatty acid derivative called palmitoylethanolamide (PEA). Therapix believes PEA may increase the efficacy of the cannabinoid while lowering the required dosage and reducing adverse effects.

  • Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
    PR Newswire10 months ago

    Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

    TEL AVIV, Israel, Dec. 4, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, announces the completion of enrollment in its investigator-initiated Phase IIa study at Yale University evaluating its investigational compound THX-110, a therapeutic compound consisting of FDA-approved dronabinol (synthetic ∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA) , for Tourette syndrome. "We're optimistic that this study will support earlier clinical research documenting the therapeutic benefits of cannabinoid-based therapies and may suggest that the combination of dronabinol and PEA, which we are developing as our investigatory compound THX-110, will demonstrate a safe and efficacious treatment for this highly debilitating disease with high unmet medical need.

  • Therapix Biosciences Spotlighted in Financial and Trade Media Outlets
    PR Newswire11 months ago

    Therapix Biosciences Spotlighted in Financial and Trade Media Outlets

    TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ --Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on ...

  • PR Newswire11 months ago

    Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

    TEL AVIV, Israel, Nov. 10, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by Raphael Mechoulam, Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board. Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model.

  • Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update
    PR Newswire11 months ago

    Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update

    - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel , Nov. 9, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical ...